ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial

Lin, Rongbo; Zhu, Jinfeng; Luo, Yushuang; Lv, Xia; Lu, Mingqian; Chen, Haihui; Zou, Huichao; Zhang, Zhichun; Lin, Shaowei; Wu, Milu; Li, Xiaofeng; Zhou, Min; Zhao, Shen; Su, Liyu; Liu, Jiang*; Huang, Cheng*哈尔滨医科大学
Journal of the National Comprehensive Cancer Network2022-9DOI: 10.6004/jnccn.2022.7034
1被引7阅读
引用收藏
分享

摘要

Background: Optimal analgesic maintenance for severe cancer pain is unknown. This study evaluated the efficacy and safety of intravenous patient-controlled analgesia (IPCA) with continuous infusion plus rescue dose or bolus-only dose versus conventional oral extended-release morphine as a background dose with normal-release morphine as a rescue dose to maintain analgesia in patients with severe cancer pain after successful opioid titration. Methods: Patients with persistent severe cancer pain (>= 7 at rest on the 11-point numeric rating scale [NRS]) were randomly assigned to 1 of 3 treatment arms: (A1) IPCA hydromorphone with bolus-only dose where dosage was 10% to 20% of the total equianalgesic over the previous 24 hours (TEOP24H) administered as needed, (A2) IPCA hydromorphone with continuous infusion where dose per hour was the TEOP24H divided by 24 and bolus dosage for breakthrough pain was 10% to 20% of the TEOP24H, and (B) oral extended-release morphine based on TEOP24H/2 x 75% (because of incomplete cross-tolerance) every 12 hours plus normal-release morphine based on TEOP24H x 10% to 20% for breakthrough pain. After randomization, patients underwent IPCA hydromorphone titration for 24 hours to achieve pain control before beginning their assigned treatment. The primary endpoint was NRS over days 1 to 3. Results: A total of 95 patients from 9 oncology study sites underwent randomization: 30 into arm A1, 32 into arm A2, and 33 into arm B. Arm B produced a significantly higher NRS over days 1 to 3 compared with arm A1 or A2 (P<.001). Daily NRS from day 1 to day 6 and patient satisfaction scores on day 3 and day 6 were worse in arm B. Median equivalent-morphine consumption increase was significantly lower in A1 (P=.024) among the 3 arms. No severe adverse event occurred in any arm. Conclusions: Compared with oral morphine maintenance, IPCA hydromorphone for analgesia maintenance improves control of severe cancer pain after successful titration. Furthermore, IPCA hydromorphone without continuous infusion may consume less opioid.

学科与关键词

关键词
SYMPTOM ASSESSMENT SYSTEMDOUBLE-BLINDMORPHINEPHARMACOKINETICSHYDROMORPHONEMANAGEMENTMETHADONEEFFICACYINFUSIONCHILDREN
相关
加载中…
  • Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
    Lin, R.; He, L.; Lu, M.; Wang, Y.; Liu, J.; Li, Q.; Lu, X.; Zhuang, L.; Zhang, Z.; Gong, L.; Luo, Y.; Cao, L.; Zhong, J.; Zou, H.; Ren, T.; Shang, C.; Lin, S.; Zhao, S.; Su, L.; Huang, C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
  • The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study
    Feng, Weineng; Wang, Yufeng; Ran, Fengming; Mao, Yong; Zhang, Helong; Wang, Qifeng; Lin, Wen; Wang, Zhidong; Hu, Jianli; Liao, Wangjun; Zhang, Tao; Chu, Qian; Xiong, Weijie; Yi, Tienan; Yi, Jiqun; Ma, Shoucheng; Sun, Yi; Meng, Lingzhan; Liu, Chunling; Zhou, Silang; Zheng, Dengyun; Wang, Shubin; Lin, Haifeng; Fang, Wenzheng; Li, Jun; Wu, Minhui*Frontiers in Medicine, 2022, 9: 918468.被引 1
  • Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
    Yu, S.; Xie, G.; Zhang, Q.; Zhang, H.; Li, P.; Lu, P.; Zhang, J.; Feng, J.; Pan, H.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of the National Comprehensive Cancer Network
发表日期
2022-09
卷期
第 20 卷, 第 9 期
页码
1013-+
DOI
10.6004/jnccn.2022.7034
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Fujian Cancer Hospital

作者

  • L

    Lin, Rongbo (第一作者)

    fujian med univ · fujian canc hosp

  • Z

    Zhu, Jinfeng

查看全部 16 位作者收起作者
  • L

    Luo, Yushuang

    qinghai univ

  • L

    Lv, Xia

    fujian med univ

  • L

    Lu, Mingqian

  • C

    Chen, Haihui

  • Z

    Zou, Huichao

    harbin med univ

  • Z

    Zhang, Zhichun

  • L

    Lin, Shaowei

    fujian med univ

  • W

    Wu, Milu

    qinghai univ

  • L

    Li, Xiaofeng

  • Z

    Zhou, Min

    fujian canc hosp · fujian med univ

  • Z

    Zhao, Shen

    fujian canc hosp · fujian med univ

  • S

    Su, Liyu

    fujian canc hosp · fujian med univ

  • L

    Liu, Jiang (通讯)

    peoples hosp xinjiang uygur autonomous reg

  • H

    Huang, Cheng (通讯)

    fujian med univ · fujian canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417